News | Astellas Pharma Inc.
WEBAstellas Receives Approval from the European Commission for VYLOY TM (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Newsroom | Astellas Pharma Inc.
WEBSep 24, 2024 · Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024. Sep 05, 2024 Press Releases. Astellas to Present VEOZAH TM (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society. EXPLORE ALL …
Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for …
WEBTOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAH TM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause 1 on May 12. VEOZAH is the ...
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
WEBApr 30, 2023 · Astellas aims to become a cutting-edge, VALUE-driven life science innovator to realize its VISION to be "on the forefront of healthcare change to turn innovative science into...
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational ...
WEBApr 14, 2023 · The primary endpoint is progression-free survival of participants treated with combination of zolbetuximab plus CAPOX compared to those treated with placebo plus CAPOX. Secondary endpoints include...
Astellas and Kelonia Therapeutics Enter into Research and License ...
WEBTOKYO and BOSTON, Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Kelonia Therapeutics (CEO, Founder: Kevin Friedman, Ph.D.,...
News | Astellas Pharma Inc.
WEBJan 29, 2024 · Latest and past news available. – Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival –– If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in ...
Astellas Receives Positive CHMP Opinion for XTANDI™ in …
WEBMar 22, 2024 · Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Astellas Pharma US, Inc. | News Room - News Releases
WEBSep 20, 2024. Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer. Read More. News / Media. Sep 18, 2024. Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure. Read More. News / Media. Sep 11, 2024.
Astellas to Acquire Propella Therapeutics - Yahoo Finance
WEBNov 15, 2023 · Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Propella Therapeutics, Inc. (President and CEO: William Moore, "Propella") today announced that Astellas,...